PWA
ENTA icon

Physician Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Physician Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46
Closed -$581 – 2369
2026
Q1 		$581 Buy
+46
New +$617 ﹤0.01% 1867

Other funds holding ENTA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return

Physician Wealth Advisors's ENTA Position: Q2 2026 in Review

Physician Wealth Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 46 shares — an estimated $581 sold.

Physician Wealth Advisors first reported a position in ENTA in Q1 2026 and held it in 1 quarter. The position peaked at $581 in Q1 2026. 9 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Physician Wealth Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Physician Wealth Advisors sold 46 Enanta Pharmaceuticals shares in Q2 2026, an estimated $581.
  • Physician Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Physician Wealth Advisors's Enanta Pharmaceuticals position peaked at $581 in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.